Natera, Inc. $NTRA Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Natera, Inc. (NASDAQ:NTRA) by 10.7% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 833,376 shares of the medical research company’s stock after acquiring an additional 80,440 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.58% of Natera worth $226,220,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of NTRA. Integrated Wealth Concepts LLC raised its holdings in Natera by 6.6% during the first quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock worth $221,000 after purchasing an additional 96 shares during the last quarter. NewEdge Advisors LLC grew its holdings in Natera by 68.3% in the first quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock valued at $644,000 after purchasing an additional 1,847 shares during the last quarter. Focus Partners Wealth increased its position in shares of Natera by 8.6% in the first quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock valued at $847,000 after buying an additional 474 shares in the last quarter. Sivia Capital Partners LLC purchased a new position in shares of Natera in the second quarter valued at $298,000. Finally, WINTON GROUP Ltd acquired a new position in shares of Natera during the 2nd quarter worth $558,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on NTRA shares. Guggenheim upped their price target on shares of Natera from $290.00 to $360.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Robert W. Baird set a $348.00 price target on shares of Natera in a report on Friday, August 7th. Wall Street Zen downgraded shares of Natera from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Sanford C. Bernstein began coverage on shares of Natera in a research report on Friday, June 26th. They set an “outperform” rating and a $310.00 target price on the stock. Finally, Piper Sandler lifted their target price on shares of Natera from $249.00 to $363.50 and gave the stock an “overweight” rating in a research note on Wednesday, August 12th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $319.38.

Insider Activity at Natera

In related news, CEO Steven Leonard Chapman sold 3,076 shares of Natera stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $266.39, for a total value of $819,415.64. Following the transaction, the chief executive officer owned 99,897 shares in the company, valued at approximately $26,611,561.83. This trade represents a 2.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Fesko sold 6,517 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $321.53, for a total value of $2,095,411.01. Following the sale, the insider directly owned 197,257 shares of the company’s stock, valued at approximately $63,424,043.21. This trade represents a 3.20% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 103,472 shares of company stock valued at $24,960,134 over the last quarter. 5.05% of the stock is currently owned by corporate insiders.

Natera Price Performance

Shares of NTRA stock opened at $321.96 on Tuesday. The firm’s 50-day simple moving average is $286.93 and its 200-day simple moving average is $234.55. Natera, Inc. has a 1-year low of $157.43 and a 1-year high of $343.18. The firm has a market cap of $46.41 billion, a P/E ratio of -236.73 and a beta of 1.51.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The firm had revenue of $752.75 million during the quarter, compared to the consensus estimate of $661.24 million. During the same period in the previous year, the firm earned ($0.74) earnings per share. Natera’s revenue was up 37.7% compared to the same quarter last year. Analysts expect that Natera, Inc. will post -1.02 earnings per share for the current fiscal year.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.